text:
US Campgrounds
North Dakota
Mcintosh County
Dry Lake
Dry Lake, North Dakota
Custom Search
The kind staff and all the cool things to do will make you feel delightful. While stopping by this vicinity in North Dakota it's a wonderful idea to go camping too.
Ok, it's about time you went camping, so what do you say? Dry Lake in North Dakota is a wonderful choice.
Dry Lake is a very popular old favorite campground among the people from Ashley. Loads of people pick this campground through their tour to Doyle Memorial State Park. It's out of the question to run out of cool things to do close to Dry Lake; it unquestionably is a wonderful campground.
As if Dry Lake wasn't enough, you can also go playing golf, and relaxing, so most likely you want to stay a bit.
During your trip to Dry Lake you'll meet some folks from Ashley for sure. Doyle Memorial State Park is a great place to stretch your legs a bit, and a game of bowling is cool at nearby Lyric Lanes & Restaurant. This is such a magnificent
campground. Places like Beaver Lake State Park are splendid to visit, and the scenery at Lake Hoskins Dam is delightful. While you're here at Dry Lake you can play some golf at Eureka Municipal Golf Course, and if you are looking for a bowling alley nearby, Ashley Lanes is in the neighborhood of Dry Lake. If you're here at Dry Lake and you like golf, you can go to Ashley Country Club. Summertime brings highs in the 80's to Dry Lake. Summer night lows descend down to the 50's. The winter comes with highs in the 10's; winter nights come with lows in the-10's to Dry Lake. Dry Lake is a location that is rather dried up usually. June is the month that gets the most rain while January is generally the driest month.
Steele Cobblestone Inn, Steele
50 miles away
Other campgrounds near Dry Lake, North Dakota:
Hoskins Lake Recreation Park, Ashley
, 2 miles away
Lake Hoskins-South Ramp, Ashley
, 2 miles away
Ashley RV Park, Ashley
, 5 miles away
Doyle Memorial, Wishek
, 7 miles away
Wishek City Park, Wishek
, 12 miles away
Lehr Wildlife Management Area, Lehr
, 13 miles away
Mundt Dam, Fredonia
, 17 miles away
Beaver Lake State Park, Wishek
, 20 miles away
Public Lands near Dry Lake, North Dakota:
Doyle Memorial State Park, North Dakota
, 7 miles away
Beaver Lake State Park, North Dakota
, 20 miles away
Golf Courses Near Dry Lake, North Dakota:
Ashley Country Club, Ashley
, 4 miles away
Eureka Municipal Golf Course, Eureka
, 17 miles away
Current weather conditions at Dry Lake, North Dakota
Local climate location: WISHEK 8 miles away
Outdoors Recreation Near Jamestown, North Dakota
Outdoors recreation in the vicinity of Jamestown, North Dakota, the metro area neareast to Dry Lake. Find info on campgrounds, marinas, hiking trails, ski resorts, lakes, beaches, parks, whitewater, golf courses and more.
North Dakota Campgrounds
Complete list of all campgrounds in North Dakota
Mcintosh County Campgrounds
Complete list of all campgrounds in Mcintosh County
Books about campgrounds in North Dakota
List of books available on Amazon.com about campgrounds in North Dakota.
Copyright © Stratus-Pikpuk, Inc.


text:
Cash basis or accrual accounting: which is best for your business?/
Did you know that there's more than one way to account for your business?
That's right. In 2013, HMRC introduced cash basis as a business accounting method for businesses with a turnover of £150,000 or less (as of 2017), so businesses could choose between cash and accrual (sometimes know as traditional) accounting.
But which one is right for your business?
Here's the information you need for both types of accounting, to help you decide.
Accrual accounting
Also known as traditional accounting, this is the method most businesses use.
If you use accrual accounting, your income is recorded when you've earned it rather than when you receive the payment, and your expenses are recorded when you incur them rather than when you pay an invoice.
So, if you invoice a client during the 2017-18 tax year but don't receive payment until the 2018-19 tax year, you would still record it as income for 2017-18.
Accrual accounting is a great option for complicated businesses such as those with high levels of stock, but smaller, more simple businesses may benefit from using cash basis accounting.
Cash basis accounting
If you run an unincorporated business with an annual turnover of £150,000 or less, you can account for your business on a cash basis.
This means that rather than accounting for payments when they are invoiced, you'll only account for them when they are paid or received.
This means that you only need to declare your income and expenses when the money comes in and out of your business. This is handy for small businesses, as they won't pay tax on income they haven't received yet.
However, there are also disadvantages.
If you're hoping to get finance for your business, cash accounting may show your profit as lower and therefore less likely to receive finance. Banks may also ask to see your accounts using accrual accounting, which will mean more work for you.
If you have already borrowed money to finance your business, you should also be aware that you can only claim up to £500 of interest or bank charges as an expense using cash accounting.
You also won't be able to offset any losses against other taxable income using this method.
It's time to swap money stress for financial empowerment.
The Independent Girls Collective is a members-only platform to help smart women like you to take control of their finances and feel good about money.
As a member, you'll get new courses, resources, live masterclasses and 1:1 coaching every month to help you manage your finances and provide the support you need to build a successful, fulfilling business that allows you to live the life you desire, as well as access to our supportive community of creative female entrepreneurs.

subset: commoncrawl


text:
The other day I was driving my car when somebody had the audacity to stop quickly. I promptly drove straight into the back of their vehicle, rear-ending them. I jumped out of my car and yelled at the obviously injured driver, berating them for being so foolish as stopping on a major roadway. Of course, it didn't matter to me that the reason they stopped was because their was a pedestrian crossing, and that this pedestrian ran out into the street, and the driver that I just hit did everything in their power to not hit that person crossing the street. How dare that driver put me at jeopardy by slamming on their brakes, when they should have just swerved around the person so I wouldn't have had to drive into the back of their vehicle.
In case you haven't figured it out. This didn't happen, scratch that, this did happen, except not as it appears.
You see when this happened, I was the person who slammed on my brakes to avoid a pedestrian who bolted into the crosswalk. Now I wasn't hurt, nor obviously injured (those details just make the opener a little more snappy), but I did encounter this stream of thought. It is absolutely amazing what we are able to convince ourselves of, but we've already talked about that...
Most of us live our lives much like I did in the story above. We wander through life, and the circumstances thereof, and we find a way to navigate it through this life completely unscathed. It is a modern day miracle. Get fired from your job. It was the economy's fault. New clothes in same size from familiar store don't fit. It's the European styling, always making things the wrong size, I definitely didn't gain weight. Marriage breaks down. Spouse was a complete idiot who needed to grow up. You never got the promotion you were hoping for. System is out to get me, Johnny, Timmy and Bobby are conspiring against me.
You get the idea.
If you are somebody who is skating through life and the only answer you can ever come up with to a negative situation is that you are the victim of circumstance, stupidity, or conspiracy, then you are doing it wrong. It is time for us to grow up and start taking responsibility. It is time to say, "Yup... that was my fault" and subsequently, "I've got to work on this... I need to get better." The only way that you are going to even scratch the surface of the potential which is inside of you is if you take responsibility, own your issues, and start working on them.
The world is not perfect, and neither are you. But if we understand that we can make a bigger impact on this world by bettering ourselves than we will be come unstoppable. I've said it once and I will said it again, the world needs the best version of you. There is to much inside of you, there has been to much invested in you for you to side that everything ever is somebody else's fault.
Jeans to tight. Get on an eating plan, and start exercising. Start small, and think long term. Got fired or maybe passed over for a promotion, dig into WHY... is it work ethic, personality, or some other reason. It's possible that you might discover that it's a team thing and that you are a duplication of a certain skill set. If you own this, you can either diversify your skills, invest in some learning, or you might take your talents to South Beach, and find a better fit for you. Either way, by owning the outcome you are becoming apart of the solution instead of being a victim of the circumstance.
Now let me be clear about something. If you are the victim of abuse, you need to understand that this is not your fault, and you do not need to own what happened to you for any reason. If you have not reported, please come forward. If you are in need of assistance, please reach out. This is not your fault and this post in no way applies to you. You are strong, you are courageous, and you will overcome this.
Here's what I'm trying to get at it. Things happen to us all the time that we can actually do something about. So instead of complaining about it, own it. Make a change, learn something, grow... it's time that we made forward progress instead of just treading water wallowing in the waters of your own self-pity. Let's be the kind of people who own it, and move forward.
Brett Esslinger is a Husband, Dad, Son, Brother, Pastor, Speaker, Leader, Writer whose life goal is to help people unlock their potential and fulfill their life's purpose.
Follow Brett on Twitter, Instagram & Facebook: @brettesslinger and of course over on Snapchat at: brett.esslinger


text:
Maintaining a balanced diet can be hard – but this supercharged daily green supplement will help you stay on track, offering a beneficial 'neutralising' impact on your system, lowering acidity levels for stronger immunity, brighter skin and reduced inflammation. WelleCo was born when Dr Simone Laubscher shared the benefits of her alkalising green powder with supermodel Elle Macpherson, who found the results so life changing that she wanted to share it with the world. Free from synthetic ingredients, this mighty powder is formulated from premium cold-pressed, bio-live super fruits, plants and herbs (including turmeric, pomegranate and goji berry, to name but a few) so that your body can easily recognise and use every precious nutrient.
A daily greens supplement that's completely free from synthetics and specially designed to balance out your body's acidity level, WelleCo's Alkalising Formula is an innovative way to maintain your body's health through the stressful demands and impact of modern life. Advocating that our bodies weren't designed to absorb synthetic supplements, WelleCo has crafted this super green multi-vitamin from all-natural, premium bio-live ingredients, so that your body can easily recognise and use every nutrient, just as it would with vegetables and fruit. The potent concoction is designed to counteract acidity and 'neutralise' your system, helping to establish balance, enhance immunity, brighten skin and reduce inflammation – and the ingredients list reads like a superfood fan's dream menu… Certified organic wheatgrass is combined with pineapple, alfalfa, spinach, goji berry, beetroot, carrot, pomegranate, acai, broccoli, turmeric, aloe vera and green tea, alongside Chinese herbs and shiitake mushrooms, all of which contain vital vitamins, minerals and antioxidants for increased energy, stronger immunity and glowing skin. In 150g and 300g sizes, this refill pouch can be added to your reusable caddy and added to water for effortless body boosting – WelleCo's {Hydrator Bottle} makes this even easier.
Add two heaped teaspoons to water – ideally in your WelleCo Hydrator Bottle – and shake or stir.
Certified Organic Barley Grass*, Certified Organic Wheatgrass*, Pineapple, Natural Pineapple Flavour, Apple, Certified Organic Alfalfa*, Spinach, Goji Berry, Apple Pectin, Fructo Oligosaccharides (FOS), L-Glutamine, Linseed Meal, Psyllium Husk, Lemon, Lime, Beetroot, Carrot, Xylitol, Natural Lime Flavour, Acai, Pomegranate, Calcium Citrate, Papaya, Probiotic Blend (Lactobacillus Acidophilus, Bifidobacterium Bifidum, Bifidobacterium Lactis, Bifidobacterium Longum), Certified Organic Spirulina*, Broccoli, Grape Seed Extract, Kelp, Magnesium Citrate, Milk Thistle Extract, Eleutherococcus Senticosus Extract, Zinc Gluconate, Dandelion Leaves Extract, Maitake Mushroom Extract, Shitake Mushroom Extract, Sweetener (Steviol Glycosides), Green Tea Extract, Tumeric, Aloe Vera, Horsetail, Copper Gluconate, Beta Carotene, D-Biotin, Selenium Methionine
View our Shipping Policy here
Need help? Contact us referencing product code WCO002
You must be signed in to leave a review
By creating an account with our store, you will be able to move through the checkout process faster, store multiple shipping addresses, view and track your orders in your account and more.
Email sent...
If there is an account associated with this email address you will receive an email with a link to reset your password.
Once you have created your new password, you may sign-in.


text:
Into the Mist
Into the Mist
from 17.50
A very mysterious and eerie scene was cast beside me as I was leaving Jenkinstown Forestry, Co. Louth Ireland. Something about fog in a forest adds so much character and photographic opportunities. This had such a horror movie feel about it, but yet held an elegantic and tranquil feeling to it all the same.
Jenkinstown Forestry, Co. Louth Ireland
All sizes priced for prints only. Frame and canvas orders available on request.
Add To Cart


text:
Would you like to download Full HD TV Wallpapers 1920x1080? Just select the image you like from the list of 26 wallpapers below and download it for free and without registration. It's easy and very simple. Markinternational.info offer you a huge collection of wallpapers, which is replenished by our users every day, so we advise you to spend a bit of your time to explore new and interesting wallpapers for your desktop on our website. Create yourself a positive mood for the whole day!
Photographer Brad Wilson and Animal Portraits
Melissani Cave – Incredible and Exquisite Natural Wonder
Navagio Bay – Paradise in Greece
Dark Hedges - a Mystical Natural Attraction in Ireland
Autumn Pumpkin Wallpaper
29 images
Collage Backgrounds
28 images
Cristiano Ronaldo Wallpaper
Fantasy Women Wallpaper
Hewlett Packard Wallpapers


text:
Investment Solutions means financial engineering and the active advisory services rendered in the context of the structured products and portfolio management. To find the right investment solutions, their adaption as well as the deployement are essential within the overall context.
Our investment solution services are tailored to the needs of our clients. Structured products allow unlimited variations of usage. It is essential that each products fits to the portfolio context and risk profile in order to benefit from the full potential of structured products.
We develop investment solutions tailored to the needs of our clients and their risk profile. Suitability is key and we actively advise our clients on the basis of his current portfolio of structured products.
The combination of independent product specialists at CAT Financial Products and investment specialists, our clients, create a true added value for every investor.
- Financial Engineering
- Ongoing product and portfolio analysis
- Investment solutions based on the risk profile and the market expectation of the client
- Research and trade ideas
- Restructuration and roll opportunities
- Suitability and risk analysis through back-testing and stress tests


text:
Today, HRC responded to White House Press Secretary's inability to answer a question about maintaining President Obama's LGBTQ non-discrimination executive order.
"Let's be clear: The Trump administration was unable to answer whether or not they would maintain basic protections for LGBTQ workers," said JoDee Winterhof, HRC Senior Vice President for Policy and Political Affairs. "The only good answer to that question is 'yes, of course we will.' And while Mr. Spicer is asking the President for his answer, we'd also like to know if he'll appoint a pro-equality Supreme Court Justice. Or will he maintain protections for transgender students? Will his nominee for Attorney General, who voted against expanding federal hate crimes law to include sexual orientation and gender identity, actually enforce hate crimes protections? Will his State Department commit to advancing LGBTQ equality abroad? We still don't know the answers to these questions. "


text:
Page 3: Investing in plant
To grow, organisations need to invest. They face many possible investment choices. Wise investment decision-making involves identifying investment opportunities that offer the best chance of a high return. The buoyant market for sandwiches offers worthwhile investment opportunities. The company has made two significant investments in sandwich manufacture.
1. In 1998 Hazlewood Foods purchased Breadwinner Sandwiches in London, with a production capacity of 1 million sandwiches per week.
2. Recently, Hazlewood Sandwiches has spent £25m to build Manton Wood in Worksop with a weekly production capacity of 3 million sandwiches: it currently produces 2 million. This factory is the world's largest sandwich plant.
In business there are several ways to appraise or evaluate the value of any contemplated investment.
A comparatively straightforward method of investment appraisal is the payback method. This involves calculating the number of years it would take a project (e.g. Manton Wood) to pay back (in cash flows) the original investment outlay.
A second method is to find the Net Present Value (NPV) of a proposal. This takes account of the fact that the repayment of an investment is distorted by inflation over time (prices usually rise over time). It recognises, for example, that a £ possessed now is worth more to a business than a £ to be earned next year and in following years, and for two main reasons: that £'s existence is more certain (next year's £ is less certain to be earned) and its purchasing power is likely to be higher because of price rises in the meantime. This method therefore calculates all cash flows in terms of today's money (NPV) and compares these with the capital to be invested in the project.
A third method, the Accounting Rate of Return (ARR), looks at profits rather than cash flows and measures the rate of return on capital employed - the organisation will have a target figure in mind.
In deciding whether to invest in the project, financial controllers at Hazlewood Sandwiches calculated the likely profits from the new factory, using a profit and loss forecast. A simplified format of this is shown below:


text:
When comparing CRM32Pro SDK vs GameMaker:Studio Marketplace, the Slant community recommends GameMaker:Studio Marketplace for most people. In the question"What are the best 2D game engines?" GameMaker:Studio Marketplace is ranked 77th while CRM32Pro SDK is ranked 85th. The most important reason people chose GameMaker:Studio Marketplace is:
About 30 free assets are available.
Ranked in these QuestionsQuestion Ranking
Pro Great tools included
EditorDPF: resource editor for managing images, tiles, sprites, sounds, etc. of your game
MSTE: tile-based parallax scrolling engine with support to Tiled Qt .TMX files
SetupProject: customized configuration system.
Pro Cross-platform
CRM32Pro works on Windows, Linux and MacOS X.
Pro Open source and free
CRM32Pro is licensed under LGPL license with full access to the source code on the website.
Pro Has a selection of free assetts
About 30 free assets are available.
Pro Reasonably priced
Most assets are under $5. The more advanced assets can usually go for around $20-$25.
Con Not as beginner friendly
C/C++ skills and general knowledge of SDL and basic game programming is required in order to get all the benefits.
Assets are only offered to Game Maker developers.


text:
Our trip around the world: details of the travel
530 days of travel across six continents. This is definitely not something that we decide overnight. 18 months of travel, to follow the sun around the globe!
In June 2018 starts the beginning of this long adventure!
We will leave for this trip to Seattle, after having lived there for three years: an extraordinary adventure, with beautiful encounters.
After a short stop in France to renew our passports, and even if most tour-du-mondistes do not necessarily prefer to visit Europe, we plan to spend the summer near the Mediterranean Sea: Italy, Croatia , Montenegro, Albania and then finish with Greece and its islands.
Europe map:
Then in order not to enter the "mon'automne" in Europe we will fly to Singapore, to visit the city, recover from this long journey, and especially allow us to be closer to a continent country that we wish visit for a long time: Oceania / Australia.
After a few weeks of backpacking, camping, road trips, .. we will leave for Asia
A stopover in Bali will allow us to relax a bit after these thousands of kilometers already traveled and we will leave for Southeast Asia to discover Vietnam, Cambodia, Laos, Thailand and Malaysia. This part will last a few months.
Do you think Asia is over for us? No ! Next step India! From north to south, we will try to go through Jaipur, Kerala, but also the foothills of the Himalayas. A good month of traveling in India will allow us to discover this country with its particular culture.
From Mumbai, we will leave Asia definitively after almost 5 months ...
Map Oceania / Asia:
Destination ... Johannesburg to continue our journey.
Africa is also a continent hardly visited during the World Tours, we have not made our main step in terms of time spent, however we have a lot of waiting (in terms of encounters, landscapes) countries that we will cross: South Africa, Lesotho, Namibia, Botswana, Zimbabwe, Zambia and thus end up Tanzania and Zanzibar. We still planned to spend 2-3 months in these countries.
Africa map:
At that moment, it will already be 1 year that we will travel, and so the days will count: 6 months remaining in order to finish the big loop. A great classic of more than 90% of the world's tours, South America. We will leave from Dar Es Salaam in Tanzania to Sao Paulo (not obvious to find direct flights, so we will probably go through Cape Town or Johannesburg, but a short stop in Europe can not be excluded).
From Sao Paulo where we will spend a few days, we will leave for Colombia which at this time has a mild weather. We will go down the entire South American continent to Ushuaia. This involves crossing Ecuador, Peru, Bolivia, Chile and Argentina.
Map of South America:
Here will end our great loop after crossing 27 countries.
Oh, by the way! This journey is just a guideline to follow, we are quite open to change it along the way.


text:
Month: March 2019
Think Like An Overcomer
WELCOME BACK. The scripture says "For whatsoever is born of God overcometh the world: and this is the victory that overcometh the world, even our faith". One of the undeniable pathways and most importantly in life is to think like an overcomer as well as moving forward into the great future God has for you. You're an overcomer. Therefore, you will think like an overcomer. Overcomers are great people. They are people of great achievement. Every person on this planet earth is designed to be great. Yes, every child born into the world is born with a seed of greatness that can be awakened and nurtured through proper thinking and persistent effort. You are one among them. Thinking like an overcomer attracts greatness and fulfillment of life purpose or direction of your destination. If things are not effecting your thinking, then they are not effecting your life. All overcomers for example, are focused. They are adaptable, imaginative, wise, and passionate. It's your responsibility to overcome your own life. Nothing else can hinder you. Your life is in your own hands and your hands alone have the capacity to shape your destiny. In accepting these responsibility, you must give attention to every aspect of life that is important to you. You must give attention to your health, relationships, vision and dreams, because most vision and dreams die from lack of nurture. You must give attention to your financial status, because nobody will. You must give attention to everything that matters, making yourself accountable to God and to the high standard you are setting for yourself. God is an overcomer and He had won the battles ahead of time and change your circumstances which you are now victorious in Him and him alone.
Dr. Bill Newman, a distinguished Australian speaker, an author of the 10 laws of leadership said, "If you want to be successful you must think until it hurts. He further said that your mind is like a muscle, it must be exercised to grow." Those who think well earn well. Great thinkers are great accomplishers. They are people that matters in the world. The reasons for so much underachievement and frustration is simply because people do not know how to get the most out of themselves. They don't know how to apply themselves for maximum performance and happiness. They don't know their basic operating laws and as a results, they waste many hours, even years, functioning far below their potential. You see, whenever your life is going well, it means that your thoughts and activities are aligned and in harmony with the invisible natural law. And, whenever you are having problems of any kind, it's almost invariably because you are violating one or more of the undeniable natural laws. They are set up to your happiness, it's vital that you become familiar with them and integrate them into everything you do in life. Overcomers are champions and heroes. People celebrate them and their act of heroism. You can never be robbed of it, when you discover the secret of the highflyers and those successful men and women all over the world, it moves you to the direction of your God-given purpose. Benjamin Disraeli said, failure to plan is planning to fail. Develop new thinking patterns which has the capacity to change your life. Remember, thinking and feeling does not produce positive action. Only positive action produces thinking and feeling. Be wise!
Thank you for reading to this end, see you again next week Monday morning for another interesting and soul uplifting spiritual and universal principles. Don't miss it. Make your comment below or visit our site @ http://www.wizzymedpower.com to "share" or "like" this post.
You will succeed!
Israel Onyije
Success Christian Leading Coach
Wizzymed Power International
- ← Previous
- 1
- …
- 3
- 4


text: Share: Comments Print April 13, 2009 at 2:41 PM Vampire news from all over Posted by Moira Macdonald Sometimes, the news just conveniently turns up in nicely themed packages. First, the trade papers are buzzing over the casting of Michael Sheen as the leader of the Volturi, an Italian coven of vampires in the "Twilight" sequel "New Moon," now shooting in Vancouver. Sheen, a Brit, is a terrific actor who's recently played lead roles in "The Queen" (as Tony Blair) and "Frost/Nixon" (as David Frost) on screen. In fact, he was so good as Prime Minister Blair that, when I saw him playing a diamond dealer in "Blood Diamond" shortly after, all I could think was "Why is Tony Blair in this movie?" And he brings some horror-movie cred, so to speak: He's played a werewolf in the three "Underworld" films. Perhaps he can give some of the young werewolves in "Twilight" some pointers. On other vampire fronts: The movie of Bret Easton Ellis' novel "The Informers" arrives in Seattle theaters next week, minus its vampire character. I saw the movie last week and was underwhelmed by the very dull decadence of it all, but was surprised to read the book (which is really a group of semi-interlocking short stories) and find that its most original character hadn't made it into the movie. Though Brandon Routh ("Superman Returns") was cast as Jamie, the '80s club-kid vampire, his scenes aren't in the final cut. Ellis, on bookforum.com, said the decision had to do with money: "Ultimately, there were budgetary concerns," Ellis says, "as well as concerns about how violent and sexual it was." He admits, though, to feeling that absence: "Nick [Jarecki, the initial director, later replaced by Gregor Jordan] and I had agreed that it needed to be in there. To lose it made the film much more serious for me, which isn't what I had in mind at all." Seeing as the film that remains is extremely violent and sexual (it's not like the decision prevented "The Informers" from being rated R), it seems a remarkably weird decision to cut a vampire from a film — or, for that matter, to cut its most over-the-top character. Maybe he'll turn up on the DVD. Or in a "Twilight" movie. Comments


text: To examine whether the cellular properties could recover from HL, earplugs were removed prior to (P17) or after (P23), the closure of these CPs. The earlier age of hearing restoration led to greater recovery of cellular function, but firing rate remained disrupted. When earplugs were removed after the closure of these CPs, several changes persisted into adulthood.


text:
Name for the next Assassin's Creed leaked by accident?/
Someone managing the fan page in Facebook made a mistake by revealing the name of the next Assassin's Creed game. Everybody assumes that it was a mistake since it was quickly brought down in minutes. But minutes is enough to get the leaked information, it seems like the next game might be called Assassin's Creed: Revelations.
Assassin's Creed's Facebook page reveals that if you share and link the info given in the fan page it will reveal the next Assassin's Creed game. I'm guessing this will officially reveal the title of the game(which was leaked by accident) and other information regarding the next game.
The fan page also revealed a teaser trailer with some clues about the game.
Is it a continuation of the current story?are we re-visiting Altair's time ? or are they giving us something entirely new, whatever it is, Ubisoft plans to officially reveal the game somewhere in May so watch out for it.
[Source: VG247]


text:
Maudie: Exquisite Portrait of the Artist by Sally Hawkins and Aisling Walsh
Maud was that rarity - a well known female painter, with a male muse.
Picasso, Monet, Renoir, Degas –every artist has their muse. So too did Maud Lewis, one of Canada's most famous folk artists, and now beautifully re-drawn by Sally Hawkins and Irish artist-filmmaker Aisling Walsh. Maud, was that rarity - a well known female painter, with a male muse.
Maud, born at the start of the 20th century, found her muse in her husband Everett, played in the film by Ethan Hawke. The film depicts a rare love story – him a loner, her disabled at a young age by arthritis, living in a tiny hut by the side of the road in Nova Scotia, selling her hand-drawn Christmas cards along with his fish. She also painted their home over their thirty years together with tangles of butterflies and flowers of colour, until it –and she – became famous across North America. She painted still when, riddled with arthritis, she could only move her hands with extreme pain.
Painting means a lot too to Aisling Walsh, who says that she "always wanted to make a film about a female painter, and as soon as I saw the script, I hoped that I'd found my story and this was it.
"I really felt 'I've got to fight to make this film.' It turned out the producers had been trying to make it for a decade, but sometimes the pieces all come together at once."
In keeping with Maudie's spirit of perseverance, it was a fight to make the film – waiting for both Sally and Ethan to be available for shooting, filming in the Newfoundland winter (if you see the film, you realise not even a Spielberg budget could recreate that amount of snow) and re-building Maudie and Everett's tiny, two-room home.
"We built an exact replica of her house, I insisted on it," Aisling Walsh recalls. "We built it by the side of the road, as hers was, in as near to a landscape as we could find. Hers was in Nova Scotia, we filmed in Newfoundland. And we never removed the walls for ease of filming – apart from anything the winter wouldn't allow for it."We shot in chronological order, so it helped to see how she transformed that dirty old hut into this beautiful, crazy place. Her greatest work of art is the house."
Maudie, however, is not just the portrayal of an artist , but the depiction of a relationship of a painter and her muse, who became her husband. Maud arrives at the shack as the servant to the almost feral Everett who values her slightly less than his hounds. In one horrible scene, he strikes her. Yet somehow they move into love.
"You've got to be so patient with films and believe they'll happen. We took three years to make Maudie which is nothing, the film I made in 2003 took me twelve years." Aisling Walsh
"It's extremely rare to have a script which details a relationship like that," Aisling points out. "The power of the relationship- the ebb and flow – you never think at the beginning this man is going to take care of her. They recover from the hitting because he realises something about himself and he changes. I have been married for a long time and nearly everyone I know identifies with aspects of the relationship."
"It's rare to see a story about the male muse of a female painter, and it's interesting to think about how differently their stories would have ended without each other. I always loved their wedding picture, a sort of Frida Kahlo and Diego Rivera.
I love seeing the relationship artists have with an individual over the years – she first sees him and puts him in a painting, and her painting changes too. Before that it's quite naïve. She realises from the start that he's important. He features in so many of her pictures."
Are the qualities of endurance and perseverance that Maudie displays so effortlessly essential to filmmakers too? Aisling Walsh believes so.
You've got to be so patient with films and believe they'll happen. We took three years to make Maudie which is nothing, the film I made in 2003 took me twelve years.
"We waited for Sally for a year, and Ethan, and you have to have an element of fatalism about it. I knew Sally would be brilliant, and something told me that Ethan was the right actor and we'd have an unique, great relationship working together on the film. That's what making these smaller indie films are all about.
"You have to be what I call 'battle ready' for a film – it's six weeks of pre-production, six weeks of filming, ultimately it becomes at least a year out of your life and then you have to let it go and move on, and all the time you're hoping you've made the right film that's in your head.
"You've also got to believe that you are going to make the film, you have to hang on. Some films take five years, some ten and some twenty to make."
But then comes Maud Lewis again with her life lesson of happiness simply in the creative process.
"Folk art often comes out of necessity," Walsh continues. "People painted walls as they couldn't afford wallpaper. But for her it was just a way of expressing herselfand whether she sold a painting or not, she would have been happy.
"She became much more well-known after her death. Since the film came out, Canada has re-gained interest in her art. Visitors to her museum in Halifax have gone up by thousands recently. I just wonder what Maudie would have made of that
Maudie is on release in the UK and Ireland from August 4 2017


text:
Some people will be happy to know:
- that I'm not going to say anything spiritual this morning; :P
- that I'm back on track–lost most of the weight that was re-gained over Easter/Mother's Day/etc., so that I'm still 10 lbs lighter than I was a year ago March;
- I have lots to do today, but I don't care!
- that I have this beautiful plant growing in my backyard:
It's called "Caladium", a tropical plant, and you can bring in the roots to keep it dormant over the winter, or just bring in the whole plant. Not that I'm going to trying lifting in this huge, hollowed-out log!
Have a great Saturday, everyone!! Great weather coming!!


text:
Tons of free guy joins porn videos and xxx movies are waiting for you on redtube find the best guy joins videos right here and discover why our sex tube is visited by millions of porn lovers daily nothing but the highest quality guy joins porn on redtube.
Watch video my brother fucking his girlfriend on redtube home of free amateur porn videos and sex movies online video length 355 starring hot amateurs gone wild in this amateur couple video.
Watch caught fucking girlfriends best friend porn videos for free here on pornhubcom discover the growing collection of high quality most relevant xxx movies and clips no other sex tube is more popular and features more caught fucking girlfriends best friend scenes than pornhub browse through our impressive.
Watch stepsister joins stepbrother and his girlfriend on pornhubcom the best hardcore porn site pornhub is home to the widest selection of free teen sex videos full of the hottest pornstars if youre craving 3some xxx movies youll find them here.
Hot sex party for two couples.
Updated weekly with exclusive videos videos stream on any mobile device all videos are available for download with no drm sort by.
Watch sassy college babe joins a fucking couple online on youporncom youporn is the largest amateur porn video site with the hottest selection of free high quality amateur movies enjoy our hd porno videos on any device of your choosing.
More tube movies you will find on this free sites below.
friends is an american television sitcom created by david crane and marta kauffman which aired on nbc from september 22 1994 to may 6 2004 lasting ten seasons with an ensemble cast starring jennifer aniston courteney cox lisa kudrow matt leblanc matthew perry and david schwimmer the show revolves around six 2030something friends.


text:
Richmond Chiropractic Offices, Inc.
Dr. Thomas RichmondBoard Eligible in Chiropractic Neurology
Palmer Graduate 1979
Pleasant Hill, CA - T & Th 10 am -1pm & 2:30-6pm
Murphys, CA - W & F 9 am -12pm and 2-5pm
Sonora, CA - Closed as of February 15, 2019
Call or Text: 209-591-0095
A Beautiful Chiropractic Office For All Your Wellness NeedsFacilityWe are proud to provide a state-of-the-art facility for the highest quality chiropractic care available. It is one of our top priorities to protect the well-being of our valued patients. Our office is run entirely by Dr. Richmond's family, making us confident that you will feel right at home in our office as we welcome all patients treat them as if they were part of our family.AppointmentsIf you would like to make an appointment, please contact our office by phone or email. Our office facilitates communications, emergency calls and appointments are welcome, especially for new patients seeking help. Although his schedule is more complex due to the three locations, we do our absolute best to answer calls and fit you in as soon as we possibly can.FinancialWe will be more than happy to submit general insurance forms for you and help you recover the most from your benefits. We will do everything we can to help you afford the treatment you need and want. Dr. Richmond works with Blue Cross, Blue Shield, Medicare, and other insurances. Forms of payment accepted by the office are check, cash, or any major credit card.
Auto AccidentsIf you have MedPay on your car insurance, all charges will be billed to the insurance for you courtesy of our office.
We would like to take this opportunity to thank you for choosing our practice for your chiropractic care.


text:
Thanks to the groomsmen, great weddings are celebrated every day. From seating her mother to holding her ring, groomsmen duty goes beyond looking good and standing at the altar. Groomsmen wear many hats; don't underestimate the role of a groomsman or the importance of giving them great groomsmen gifts that will be cherished for years to come.
Whether choosing groomsmen (or female honor attendants), groomsmen attire, the best groomsmen gift, a groomsmen poem, or the right wedding gift idea for groomsmen, the decisions and choices are enough to make your head spin!
Several online guides and resources are available to the bridegroom and groomsmen alike. Every facet of gathering and grooming the groomsmen are discussed in great detail. Simple suggestions, sensible advice, and food for thought will help you and your groomsmen make the right decisions for a smooth and successful wedding. In addition, following recognized guides can offer readers wedding ceremony tips, honeymoon advice, and much more.
If you're a groomsman, knowing your roles, what you should say, are expected to do, and what gifts to give can minimize the stress of being involved in a wedding. If you're the groom, member of the bridal party, relative, or wedding guest, you know it's a crazy time. Knowing exactly how to select the groomsmen, what the groomsmen do, how they should look, and when to let them run the show is not easy. Additionally, the differences between what's acceptable and what's expected often conflict with what you really want. Your vision of the wedding, with delicate diplomacy, can be achieved if carefully planned and gently handled.
Knowing that the definition of great groomsmen and thoughtful groomsmen gifts hinges on the appropriate preparation by the groom and the guidelines he sets, it is of utmost importance that an appropriate amount of time be spent by the bridegroom to ensure all goes according to plan. If you want your groomsmen to be there for you in spirit on your special day, it would be advised that the groom passes his thoughtfulness on the days preceding the actual wedding ceremony. Never underestimate the importance of giving your trusted groomsmen a unique groomsmen gift that they will cherish forever, and the value of the thought that went with it.
Remember, great groomsmen are possible. With the right resources, smart planning, and a little patience, the perfect wedding can be seamless and sensational!


text:
Trip is an interesting experiment in the world of comics. It's written and drawn by two female creators: Kelly Matten and Walker Farrell. Their art interchanges throughout the story like a relay baton and like any good relay they are perfectly synchronized. It's not that the creators share a similar style either; both styles are distinct but similar in fundamentals. By that I mean that the contrast isn't so sharp that you're put off by the change. Personally I enjoyed both styles, but I would bet that most people would favor one style over the other as per most people's nature. The story kicks off at a house party. We meet one of our main characters, Vee, as she scopes the party out. She doesn't really recognize anyone at the party and questions who they all are and what they're doing there. Vee heads up stairs to find the host, her friend Leo. He's loaded up on some psychedelic drugs so Vee doesn't get much conversation out of him, but he invites her to partake in his "birthday cake" to which she gladly does. Vee snags a second slice of "cake" for later and heads back down to the party. It's here that we meet our second main character Luna or Lou. She's standing with the fridge door open looking pretty lost when Vee walks up to the fridge as well. It could be that Vee just senses how stiff and awkward Lou is at the party or maybe something else, but eventually she gives Lou her second pill aka "cake" and excuses herself.
The story follows Lou for a bit as she heads back to her friend that she came with. It's a typical childhood friendship in which both people have outgrown the other, but neither is willing to admit it or aware of it. Lou becomes frustrated with her friend who is drinking and likely taken some "cake" of her own, because she was supposed to be the designated driver. Lou decides to leave and take the bus home, but when she reaches into her pocket to pull out her bus pass she also pulls out the pill. At this point her life comes to a fork in the road and she must decide if she'll stay or if she'll go.
The story is about self-discovery. The main characters of Vee and Lou are both taken on a metaphorical "trip" of sorts in which they both re-evaluate their lives. Now that doesn't mean that they both have the same "trip" or come to the same conclusion of where their life is going. Quite the opposite really, but by telling you it wouldn't be much fun for you to read and see how their paths differ.
The writing is solid. I don't know if it's due to the creator's animated backgrounds or just the look of the series, but it comes across as an animated short adapted to comic form. That's not a slam by any means, as that style has produced some of my favorite comics of all time. I liked the message and how the drugs were handled. By no means is the book saying "everyone do drugs and you'll find yourself", in fact at the end of the book they say the opposite; that this story is a possibility, but not the road map for every experience. The creators approach the subject matter responsibly and it shows. That's not all the story is about though, there are plenty of other themes like: Friendship, respect and happiness to name a few.
The pacing of the story is fast. The book is over and done with before you know it and while that's okay, I did want more time with the main characters. It's in this weird cusp of either being just a few pages short of hitting the sweet spot or a few pages over. I couldn't decide. The dialogue was very good throughout the story. It was believable and never was it annoying.
The art is definitely the strongest aspect of the book. As I said in the beginning I was partial to both styles as they fit their respected pages. In talking with Kelly Matten she told me that they each picked their pages that they wanted to illustrate and it shows. Each page really does have the same amount of care and attention. It's a great reading experience because of it. Instead of filler panels or thumbnails that "just needed to be done", you're given a story that two people enjoyed creating from beginning to end. Again the book has an animated vibe to it that I think most comic fans would really enjoy.
Trip is a good read and I enjoyed it. I think the messages it delivers are ones that we always need reminding of and while I do think the narrative could have gone deeper, it didn't necessarily hurt the story. There aren't a lot of comic books out there like Trip and especially not ones that are aimed at women; for that reason I'm very glad that it exists and I hope the creators find other stories for Vee and Lou in the future because I can't be the only one that wants to check in on them.
Score: 3/5
Creators: Walker Farrell & Kelly Matten Publisher: Solid Sauce Price: $15.00 Website


text:
District Home
New Waverly Intermediate School
New Waverly Junior High School
New Waverly High School
Staff Email
Staff Resources
Contact Us
About Us
About New Waverly Elementary
Principal's Message
Counselor's Corner
Staff Directory
Academic Calendar
Calendar of Events
Kid's College/Stride Academy
Parent Portal
Handbook & Policies
Registration & Enrollment
School Supplies
Booster Clubs
Community Information
Principal's Message
About Us
Principal's Message
Welcome to New Waverly Elementary!
We strive each day to bring out the best in each student! We remind the students each morning that each and everyone of them are smart, intelligent, and that they can do it!
It takes each and every one of us to provide a learning environment in which each child feels safe, has the tools in which he/she can learn at his/her own pace, and the means for advancing each child.
Communication is a two-fold process and the staff members here at New Waverly Elementary are committed to keeping each other in the loop, the parents, and the students so that we can all reach the common goal…education for each individual child.
Please assist us by talking to your child each night about their school work, help them with their homework, and embrace reading in your home. Reading is key at the early stages of learning and making time to read with your child, taking a moment to model reading for them, and encouraging their reading are key components of success. As they read, limit their technology/television time and really promote reading of books, magazines, and communicating one-on-one with your child. Math is also important, make time for your child to practice the math facts that he/she is presented with in class.
Attendance is very critical for your child's success. They must be here every day in order to not miss out on pertinent information. Please encourage and have your child here at school every day.
We encourage participation from parents and have many volunteer opportunities throughout the year. If you are interested, please do not hesitate to let the front office or your child's teacher know that you are available for various projects/volunteering throughout the year.
Our theme this year is, "Team Waverly, we work as a team here at NWES!" We are encouraging unity and working together just as football teams, baseball teams, basketball teams, cheer squads, drill teams, etc… Students are encouraged to wear their favorite team jersey on Mondays! We are talking to our students now about the importance of good decisions now for their future, life after New Waverly ISD…college, armed forces, technical school, trade school, etc… We believe that it is never too early to educate our students about what it takes to succeed in today's world.
We would like the parents and community to know that we consider you all part of our team. WE cannot get everything done without you all in our system. Please feel free to volunteer or assist throughout the year. Thank you in advance!
Blessed wishes for a safe and productive school year,
Mrs. Tiffany Wedgeworth, Principal
Quick Links
2019-2020 Academic Calendar
AR Book Finder
2016-17 Campus Report Card
2016-17 Federal Campus Report Card
Lunch Information
2018-2019 NWES Student Handbook
Parent Portal
Pre-K Family Engagement
Registration & Enrollment
STOPit Solutions


text:
We present the results of a multicenter clinical trial using Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) generated from EBV-seropositive blood donors to treat patients with EBV-positive posttransplantation lymphoproliferative disease (PTLD) on the basis of the best HLA match and specific in vitro cytotoxicity. Thirty-three PTLD patients who had failed on conventional therapy were enrolled. No adverse effects of CTL infusions were observed and the response rate (complete or partial) in 33 patients was 64% at 5 weeks and 52% at 6 months. Fourteen patients achieved a complete remission, 3 showed a partial response, and 16 had no response at 6 months (5 died before completing treatment). At 5 weeks, there was a significant trend toward better responses with higher numbers of CD4+ cells in infused CTL lines (P = .001) that were maintained at 6 months (P = .001). Patients receiving CTLs with closer HLA matching responded better at 6 months (P = .048). Female patients responded better than male patients, but the differences were not statistically significant. Our results show that allogeneic CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for individual patients. The response rate in this poor prognosis patient group is encouraging.
Posttransplantation lymphoproliferative disease (PTLD) is a common complication of solid organ transplantation that carries a high morbidity and mortality.1 The majority of tumors are of B-cell origin and are associated with Epstein-Barr virus (EBV). EBV is a herpes virus that induces proliferation and transformation of B lymphocytes in vitro and is associated with several human B-cell tumors including Burkitt lymphoma and Hodgkin disease.2,3 Most people acquire EBV silently during early childhood, but if primary infection is delayed until after puberty then it is associated with infectious mononucleosis (IM) in around 25% of cases.4 More than 90% of adults carry EBV as a persistent infection of B lymphocytes. Cytotoxic T lymphocytes (CTLs) that recognize both latent and lytic viral antigens are important in controlling EBV reactivation.5 EBV-specific CTLs are readily detectable in peripheral blood of healthy seropositive carriers, but in transplant recipients, who require immunosuppressive drugs, the activity of virus-specific CTLs is suppressed, thus predisposing the patients to PTLD. In addition primary EBV infection following transplantation carries a high risk of PTLD, and since most recipients who are EBV seronegative before transplantation are children, there is an increased incidence of the PTLD in the pediatric transplant population.6,7
PTLD is most common within the first year following transplantation during high-dose immunosuppression, but may occur at any stage, even after several decades.8 The clinical presentation of PTLD is variable and it is often difficult to diagnose. Lesions may be single or multiple, nodal or extra nodal—common sites being the gut, brain and transplanted organ. PTLD may present as an IM-like syndrome particularly following primary EBV infection. The tumor encompasses a spectrum of histologic types ranging from hyperplasia to monomorphic lymphoma.8 Early lesions may be polyclonal with progression to monoclonality. In EBV-associated PTLD, tumor cells contain viral DNA and express the small EB-encoded RNAs (EBERS) and a variety of viral proteins. Most tumors show full latent viral gene expression (EB nuclear antigens [EBNAs] 1, 2, 3a, 3b, 3c, and leader protein [LP]; latent membrane proteins [LMPs] 1, 2), with a few cells expressing lytic cycle genes. Expression of the EBNA 3 proteins, which are immunodominant for CTL responses, indicates that most PTLD tumors grow opportunistically in the absence of effective T-cell control of the persistent virus infection. However viral antigen expression is variable within and between tumors, some showing more restricted forms of latency either without evidence of EBNA 2 and 3 proteins, or a Burkitt-like EBNA 1 only phenotype.9
First-line treatment for PTLD is immunosuppression dose reduction, which is successful in inducing tumor regression in a proportion of cases.10 However this treatment may be limited by the onset of graft rejection due to reduced immunosuppression, and other forms of treatment such as chemotherapy, radiotherapy, and rituximab (anti-CD20 monoclonal antibody) are often required.11,12 Despite these treatments, the overall mortality from PTLD in solid organ transplantation is around 50%.13 Another approach to PTLD treatment is to enhance the EBV-specific CTL response that is suppressed in transplant recipients. Cytotoxic T-cell therapy to prevent and/or treat PTLD was first used successfully in allogeneic hematopoietic stem cell transplant recipients where stem cell donor's peripheral blood was used as a source of EBV-specific CTLs for infusion.14–16 However, since donor blood is not generally available for solid organ recipients with PTLD, we established a frozen bank of 100 EBV-specific CTLs generated from the peripheral blood of Scottish blood donors.17 We previously conducted a pilot study in which 8 patients with progressive PTLD were treated with these CTLs selected on the basis of best HLA matches between the CTL donor and PTLD patient. Three patients attained complete remission.18 In this present study, we used these partially HLA-matched allogeneic CTLs in a phase 2 multicenter clinical trial to treat 33 patients (31 solid organ and 2 stem cell transplant recipients) with biopsy proven EBV-positive PTLD that had failed conventional treatment. The overall response rate was 64% at 5 weeks and 52% at 6 months.
Patients, materials, and methods
Study design
This phase 2 multicenter clinical trial aimed to test the safety and efficacy of banked allogeneic EBV-specific CTLs used on a best HLA-match basis to treat PTLD. Inclusion criteria were as follows: biopsy-proven EBV-positive PTLD and a tumor where response could be measurable. Exclusion criteria were as follows: pregnancy and Karnofsky scale of 10 or lower. Standard therapy involved weekly intravenous infusions of CTLs (2 × 106 CTLs per kg body weight) for 4 weeks—doses established previously in a pilot study.18 Patients from 19 transplantation centers were recruited to the trial (listed in "Acknowledgments") with informed written consent from patients or guardians obtained in accordance with the Declaration of Helsinki. Preliminary data from the first 7 patients included in this trial were published elsewhere.18 The trial was approved by the Multicentre Research Ethics Committee for Scotland and by local research ethics committees for each center. This trial was also registered with European Clinical Trial Database, ClinicalTrials.gov, and the United Kingdom National Cancer Research Network.
Cytotoxic T-cell bank and in vitro testing
The establishment and management of the CTL bank have been reported elsewhere.17 Briefly, peripheral blood mononuclear cells (PBMCs) were obtained from HLA-typed, EBV-seropositive blood donors at Scottish National Blood Transfusion Services with informed consent. Lymphoblastoid cell lines (LCLs) were established by in vitro EBV infection and used as stimulators to grow EBV-specific CTLs by published methods.17 CTLs were tested in standard chromium release assays for cytotoxicity against autologous phytohemagglutinin (PHA)–stimulated blasts, autologous and mismatched LCLs, and K562 cell line to detect NK-cell activity. When deemed EBV specific, CTLs were screened for bacterial, viral, and fungal contaminants; stained and analyzed by fluorescence-activated cell sorting (FACS) (for TCRαβ, CD3, CD4, CD8, CD19, CD16/7, CD56, CD57, and a wide range of T-cell activation and differentiation markers); and then frozen in vials until required.17
Patient/CTL matching procedure
HLA A and B antigens were typed by a one-stage microcytotoxicity test using the First and Second Lambda monoclonal class I 72-well trays (One Lambda, VH Bio, Newcastle, United Kingdom) and HLA DR by low-resolution polymerase chain reaction (PCR).17 The HLA profile (A, B, DR) of the potential CTL recipients was used to identify the closest matched banked CTLs and 2 to 3 CTLs were thawed and tested for cytotoxicity in chromium release assays against autologous LCLs and PHA blasts, K562, patient PHA blasts, and, where available, patient LCLs. The CTLs showing the highest specific killing against patient LCLs with low killing of patient PHA blasts and K562 were selected for infusion.18
The diagnosis of PTLD and its classification were determined by routine histologic examination. EBER staining was carried out by in situ hybridization using a commercial kit (Dako, Cambridge, United Kingdom), and EBNA 1 and 2, and LMP 1 expression were detected by routine staining using commercially available antibodies (EBNA 2 no. M7004, LMP-1 no. M0897 from Dako; EBNA 1 no. Ab8329 from AbCam, Cambridge, United Kingdom) and detection system (Dako EnVision kit) after antigen retrieval (pressure cooking 3 minutes at pressure in Tris/EDTA). Tumor cell clonality was assessed by in situ hybridization for κ and λ mRNA (Dako).
Patient monitoring
Tumor response (complete, partial, or no response) was recorded 5 weeks and 6 months after CTL therapy as determined by clinical evaluation, imaging (x-ray, computed tomography [CT], magnetic resonance imaging [MRI] scan as appropriate) or endoscopy, and was decided by the physicians involved in patient care. Clinical monitoring was carried out weekly for 4 weeks and then at regular intervals for 6 months. A complete response (CR) was defined as complete disappearance of all measurable tumor masses and any other manifestations of disease.19 A partial response (PR) was achieved if the overall tumor mass decreased 50% or more in size where tumors were measurable clinically and/or by imaging and the patient's clinical condition remained stable or improved. No response (NR) was defined as tumor masses that remained the same size or increased in size and/or the patient's clinical condition deteriorated.
Quantitative EBV load by real-time PCR
EBV DNA levels were monitored by real-time PCR of EBV polymerase gene using Corbett Rotor-gene 3000 machine (Corbett Research, Cambridge, United Kingdom) in PBMCs taken before and after each CTL infusion and thereafter at clinical monitoring sessions.20 Briefly, DNA was extracted using QIAamp DNA Mini Kit as per the manufacturer's instructions (Qiagen, Crawley, United Kingdom) and stored at −70°C. DNA (5 microliters [μL])/1 μg) was then amplified in a 25-μL reaction volume containing primers and Taq polymerase (Promega, Southampton, United Kingdom). EBV-positive Raji cells were used to obtain a standard curve from a dilution series starting with 100 μg DNA/tube and then 10-fold serial dilutions to give a final concentration of 10 pg DNA/tube. Viral DNA copy number in test samples was estimated by extrapolating from the Raji standard curve. β-Globin was always included in each PCR run as a house keeping gene. EBV load in test samples was expressed as the relative copy number normalized against the amount of amplified β-globin DNA.
T-cell receptor (TCR) spectratyping
Functionally rearranged TCR β chain variable (BV) gene subfamilies were amplified across the complementarity determining region 3 (CDR3) encoding regions using 23 subfamily-specific primers and a FAM-conjugated β chain constant region–specific primer.21,22 RNA was extracted from 5 × 106 PBMCs or CTLs using the Rneasy mini kit and Qiashredder system (Qiagen) as per the manufacturer's instructions and was converted to complementary DNA (cDNA) using random hexamers and the Thermoscript RT system from Invitrogen (Paisley, United Kingdom). PCR amplifications were performed on 1 μL cDNA in a total volume of 20 μL containing variable and constant primers and 0.5 U of Amplitaq Gold (Applied Biosystems, Foster City, CA) polymerase. PCR product (1 μL) was diluted in 10 μL nuclease-free water and then further diluted 1 in 10 with Hi-Di formamide (containing Genescan 500LIZ size standard) before electrophoresis in an ABI 3730 (Dye set 5) automated sequencer. ABI Genemapper software (version 3.7) was used to analyze data (Applied Biosystems).
Alloantibody screen
Pre- and post-CTL infusion sera were tested for antibodies directed against mismatched HLA antigens on the infused CTLs by microlymphocytotoxicity assay. Briefly, serum samples were screened against a selected panel of peripheral blood lymphocytes from 50 HLA-typed volunteers, for the detection of class I antibodies and 30 patients with B-cell chronic lymphocytic leukemia for the detection of class II antibodies. Antibody screening was performed using the standard microlymphocytotoxicity assay, initial incubation time (45 minutes) with extension (120 minutes) after complement (Cedar Lane, Hornby, ON). Target cell viability was assessed after staining with acridine orange and ethidium bromide. Antibody specificities were identified by computer-assisted analysis (using 2 × 2 contingency tables) of panel reactivity profiles.
Statistical analysis
Statistical analysis was carried out on an intent-to-treat basis. The overall survival rate was calculated by nonparametric Kaplan-Meier method. Fisher exact test was used to identify those patient characteristics that were significantly associated with treatment response (complete or partial). For quantitative characteristics (eg, time between transplantation and PTLD development and level of EBV-specific CTL killing) a chi-squared trend test was conducted to examine whether the proportion of patients responding to treatment either increased or decreased across the levels of the characteristic. Multivariate analysis of complete and partial responders was not possible because of the limited number of patients in each group. All analyses were conducted using Stata 9.0 (Strata Corp, College Station, TX).
PTLD patients
Thirty-three patients were recruited to the trial. Five patients (2 males and 3 females) died from causes unrelated to the CTL therapy before completing the course of treatment (patients 29-33; Table 1). These patients were severely ill (widespread primary disease, bacterial/fungal septicemia, multiorgan failure, severe graft rejections) prior to CTL therapy but were nevertheless included in the intent-to-treat analyses.
Of the 33 PTLD patients in the trial, 19 were male and 14 female; the age range was 1 to 76 years (Tables 1, 2). Transplant types were as follows: stem cell, 2; heart, 2; kidney, 13; liver, 10; liver and small bowel, 3; lung, 2; heart and lung, 1. Details of time from transplantation to PTLD development, histologic types and sites of PTLD, and pretransplantation EBV serostatus (where available) are shown in Tables 1 and 2. All patients had immunosuppression dose reduction before receiving CTL therapy (stepwise dose reduction or immediate maximum dose reduction or complete withdrawal of immunosuppression according to individual transplantation centers' protocols). Twelve patients had additional rituximab and/or antivirals, and 8 had chemotherapy and/or radiotherapy (Table 1). With the exception of 3 patients (patients 13, 21, and 30) receiving concurrent rituximab and 3 patients (patients 15, 18, and 23) with continued immunosuppression dose reduction, all other patients had stopped all forms of therapy 2 to 8 weeks before starting CTL and were considered for CTLs due to their progressive or nonresponsive disease and in some cases, impending graft rejection. Their immunosuppression was re-escalated before CTL infusions. Tumor biopsies from all patients were positive for EBERs by in situ hybridization.
The 33 PTLD trial patients were enrolled from 19 transplantation centers; 19 were treated as inpatients and 14 received CTL infusions as outpatients. Twenty-three patients received 4 CTL infusions, but individual patients received 1 (patients 12, 30, and 33), 2 (patients 17, 29, and 31), 3 (patient 32), 6 (patient 22), and 8 (patients 14 and 21) infusions.18 The infusions were well tolerated with no evidence of acute infusion reactions. No adverse effect on the transplanted organ or evidence of CTL-versus-host disease was observed.
Clinical response to CTL infusions
At 5 weeks after the start of CTL infusions, 21 patients (64%) showed a response (complete or partial) to therapy and 12 patients did not respond (Tables 1–2). Twelve patients achieved a complete response (CR) defined as complete PTLD tumor regression and improvement in graft functions and clinical status, and 9 patients showed a partial response (PR) defined as clinical improvement and 50% reduction in overall tumor mass where tumors were measurable clinically and/or by imaging. The 5 patients who died before completion of CTL treatment were classified as nonresponders.
The overall survival rate is shown in Figure 1. At 6 months, 26 patients (79% survival) were still alive (Tables 1, 2). One patient who showed a partial response to CTL therapy at 5 weeks died 3 months later from severe cytomegalovirus infection (patient 21, she was in CR at the time of death), and one patient from the NR group died due to an extensive tumor burden (patient 22). Three patients who initially had shown a partial response relapsed by 6 months.
Two patients with partial responses at 5 weeks achieved complete response at 6 months bringing the number of patients showing CR to CTL therapy to 14. One CR patient has since relapsed and 13 remain disease free, 1 to 7.5 years after completing CTL therapy.
Two of the 3 patients (patients 15 and 16) with PR at 6 months are still alive (18 and 20 months after infusions, respectively). Patient 15 had a further course of reduction of immunosuppression. The third PR patient (patient 17) had a relapse and died 7 months later.
Thus, overall a response (complete or partial) to CTL therapy was recorded in 21 (64%) of 33 patients at 5 weeks and 17 (52%) of 33 patients at 6 months. Because the number of participants is relatively small, partial and complete responders were aggregated for comparison with the nonresponder group in further analyses.
Response in female compared with male patients
The response was better among female than male patients at both 5 weeks (79% versus 53%, respectively) and 6 months (71% versus 37%, respectively), but these differences were not statistically significant (Table 2). However, when analyses were restricted to 28 patients who successfully completed treatment, the results became significant: at both 5 weeks and 6 months all (11 of 11 and 10 of 10, respectively) female patients showed a response, whereas at the same time points, 10 of 17 and 7 of 16 male patients responded (P = .02 at 5 weeks and P = .004 at 6 months). There was no association between the sex of CTL donors or CD4 T-cell counts in CTLs and sex-related response (data not shown). The age of the patients did not affect outcome.
EBV serostatus, time of onset of PTLD, and outcome
Pretransplantation EBV serology was available from 17 of 33 patients (Table 1). Ten patients were seronegative before transplantation and developed PTLD following primary EBV infection. Seven (70%) of these 10 previously EBV-seronegative patients showed a response (6 CR and 1 PR) to CTL at 6 months compared with 2 (29%) of 7 patients who were already EBV seropositive before transplantation.
The interval between transplantation and PTLD development varied from 6 weeks to 19 years (median time, 3.5 years). The response at 5 weeks to CTL therapy did not differ significantly between early and late onset of disease (Table 2): 9 (64%) of 14 early (PTLD < 2 years after transplantation) compared with 12 (63%) of 19 late (PTLD > 2 years after transplantation) PTLD responded (P = .999). At 6 months, all 9 of 14 patients with early onset disease showed a sustained response, whereas only 42% (8/19) of patients with late onset PTLD maintained the initial response (P = .30).
Degree of HLA matching
CTL lines used in the trial were selected for individual patients on the basis of the number of HLA matches (A, B, and DR), with preference given to HLA class I antigen (A and B) matching as EBV antigens expressed in relation to HLA class I molecules are known to be the main targets for CTLs.5 The number of HLA matches at HLA A, B, and DR loci varied from 2 of 6 to 5 of 6, and there was an association between the number of matches and patient outcome, with those with a higher number of matches responding better at 6 months than those with fewer matches at 6 months; this reached a statistical significance (P = .048; Figure 2; Table 2). The response rate was not related to matching or mismatching of any particular HLA antigen locus (A, B, or DR; data not shown).
Better outcome with higher percentage of CD4 cells in CTLs
All CTLs used for in vivo infusions were polyclonal and contained both CD4+ and CD8+ cell populations, with the percentage of CD3+, CD4+ cells ranging from less than 1% to 60%. At 5 weeks after the first infusion, there was a statistically significant trend (P = .001) toward better responses in those receiving CTLs with a higher percentage of CD4 cells. Responses for patients receiving CTLs with less than 1%, 1% to 4.9%, and 5% or more CD4 cells were as follows: 3 (25%) of 12, 7 (78%) of 9, and 11 (92%) of 12, respectively (Figure 3). This significant trend was maintained at 6 months with 2 (18%) of 12, 5 (56%) of 9, and 10 (83%) of 12 patients responding, respectively (P = .001) (Figure 3).
CTL cytotoxicity and outcome
The level of EBV-specific CTL killing in vitro of the autologous LCLs measured prior to CTL infusion ranged from 19% to 74%, and CTL killing of the patient LCLs (determined either prior to or following the CTL infusions depending on when the LCLs became available for testing) ranged from less than 1% to 60%. No association was seen between level of in vitro killing of autologous or patient's LCLs by CTLs and tumor response (data not shown).
PTLD morphology and outcome
Prior to CTL therapy, 29 patients had tumors at multiple anatomic sites, whereas 4 were single-site tumors (Table 2). Three (patients 2, 5, 11) of the 4 single-site tumors showed a complete response to CTL therapy, and this response was maintained at 6 months. In comparison 18 (62%) of 29 tumors involving multiple sites showed a response at 5 weeks, and this was reduced to 14 (48%) of 29 at 6 months. Five patients had PTLD involving the central nervous system; 4 (patients 13, 14, 21, 26) with multiple lesions in brain parenchyma, of which 2 achieved a complete response at 6 months, 1 had no response, and 1 showed a partial response at 5 weeks but later died of cytomegalovirus infection (autopsy showed complete regression of the tumor). The other patient (patient 24) with widespread PTLD involving eye, spine, and lymph nodes did not respond to CTLs.
There was no significant association between response to CTL therapy and histologic type, clonality, or viral gene expression of the PTLD tumors; however, it was notable that 4 (80%) of the 5 hyperplastic tumors and all 5 Hodgkin-type PTLDs responded to CTLs compared with 56% and 50% response rates for polymorphic and monomorphic tumors, respectively (Table 2). The only Burkitt-like tumor showed a complete response that was sustained at 6 months (Table 1).
EBV viral load in peripheral blood
EBV DNA was detected in PBMCs of 17 of 33 PTLD patients tested before the first CTL infusion, the viral load ranging from 339 to 1.22 million copies per million PBMCs. Pre-CTL infusion levels of EBV DNA for all 33 patients are shown in Table 1. Four (patients 22, 24, 27, and 31) of 9 patients who had received prior anti-CD20 monoclonal antibody rituximab had detectable EBV DNA in their PBMCs before CTL infusion.
Ten of the 17 patients with preinfusion EBV DNA later showed a complete/partial response to CTL therapy and 7 patients had no response. Viral load fluctuated during the CTL infusions and became undetectable between 1 week to 8 months after the last CTL infusion in all patients (Figure 4A). There was no association between the rate of decrease in viral load and the response to therapy (Figure 4B represents patient 18, PR at 5 weeks, NR at 6 months). Some patients (including 9 who had no detectable DNA before CTL infusion) showed a transient increase in EBV load in PBMCs immediately after CTL infusions (Figure 4C; patient 2 CR).
Monitoring of infused CTLs
T-cell receptor (TCR) spectratyping was performed on preinfusion and serial postinfusion PBMCs from 5 patients and on the infused CTLs. The timing of samples tested ranged from 4 hours to 7 days after infusion. The number of monoclonal TCR subfamilies identified in the infused CTLs ranged from 2 to 8 (average number, 4) with no specific pattern of family usage nor any particular subfamily being dominant. Where possible the monoclonal subfamilies identified in the CTLs were traced in the patient PBMC samples. For successful tracing, the CTL monoclonal subfamily signal had to be strong with the same base pair peak in the pretreatment recipients' PBMC producing a weak signal. Tracing was successful in 3 of the 5 patients (1 complete responder, 1 partial responder, and 1 nonresponder), with a total of 7 subfamilies traced over the treatment period (2, 4, and 6 infusions). Two different patterns of CTL subfamily trace were observed; a gradual increase in the peak signal with each infusion (2 of 7 subfamilies) and a maximum signal detected at 4 or 24 hours after each infusion (5 of 7 subfamilies; Figure 5A, B, PR and NR, respectively). In one patient, an elevated CTL subfamily could be detected 7 days after the second infusion, but no further samples were available to test.
Monitoring of alloantibody response
Testing of pretransplantation and posttransplantation plasma samples from all trial participants revealed that only one patient had developed an antibody response against a mismatched donor HLA antigen (A2; data not shown).
We report the first phase 2 clinical trial using partially HLA-matched allogeneic CTLs for PTLD therapy. Using EBV-specific CTLs grown from peripheral blood of healthy blood donors to treat PTLD on a best HLA-match basis, we show a 52% (17/33) response rate at 6 months. CTL infusions proved simple to administer on an outpatient basis, and no treatment-related acute or long-term toxicity was observed. Thus, since all patients in the trial had failed to respond to conventional PTLD treatments, our response rate of 52% with allogeneic CTLs is encouraging and represents a new, safe, and alternative approach to treating PTLD.
Previous studies using donor-derived EBV-specific CTLs to prevent or treat PTLD in stem cell transplant recipients have reported promising results, but this strategy cannot be used for PTLD in solid organ recipients as donor blood is generally not available.14,15 For solid organ recipients, autologous CTLs have been used with some success, but the time and expense required to generate individual CTLs for each patient restricts its wider application.23–25 To bypass these restrictions, we developed a CTL bank in Edinburgh that provides a source of EBV-specific CTLs for rapid treatment of PTLD on a best HLA-matched basis.
The primary outcome measure in this trial was tumor response at 6 months as indicated by clinical evaluation in addition to radiologic or MRI scanning where appropriate. Twenty-six of the 33 patients reached the 6-month time point with a response rate (partial or complete) of 52% (17/33). There was a suggestion that response to treatment may be better among female than male patients, but a larger trial is needed to confirm this. If such a difference exists, then the reasons are not clear.
In common with previous studies using conventional PTLD treatment, our results show some indication of a better, sustained response to CTL therapy in early onset disease.26 Thus, we found that PTLD tumors arising within 2 years of transplantation showed a better response rate at 6 months than those arising at a later time point (64% versus 42%), although the differences were not statistically significant. It is notable that 3 of 4 tumors involving a single anatomic site showed a complete response.12,26 At the time of enrollment into our trial, most patients had progressive disease despite having received conventional therapy. In particular, immunosuppression dose reduction was first-line treatment for all patients (Table 1), and for this reason we cannot exclude the possibility that some of the responses we observed were due to the delayed effect of this treatment rather than CTLs. However, we have previously reported complete tumor regression after allogeneic CTL therapy in a child with an EBV-associated brain lymphoma related to a primary immunodeficiency, a situation in which the level of immunosuppression could not be manipulated.27
The CTLs used in this study were selected for infusion on a best HLA-match basis, with the number of matches at HLA A, B, and DR loci varying from 2 to 5. We recorded a significant increase (P = .048) in response rate with increased number of HLA matches between CTL donor and recipient, again indicative of the tumor responses being CTL mediated (Figure 2). The CTL lines in the Edinburgh bank were derived from healthy donors and, in order to maintain multiple epitope specificities, were not cloned prior to in vivo use. Most lines consist of CD8 T cells with a minor population of CD4 cells.17 The outcome of CTL therapy in this trial correlated with the level of CD4 cells within CTLs, with a highly significant improvement in outcome with higher numbers of CD4 cells (Figure 3). This is not an entirely unexpected result as CD4 cells provide help to CD8 cytotoxic T cells, and although most CD8 cells in the CTLs had an effector phenotype (CD45RO+, HLA-DR+, CD69+, CD150+), CD4 cells may have provided additional signals that enhanced their survival in vivo.
Although the timing of the fall in EBV load in peripheral blood that we regularly observed during and following CTL therapy suggests that the CTLs were active in vivo, it is important to note that the rate of fall did not correlate with response to tumor (Figure 4). Thus events in the peripheral blood do not always reflect those in the tissues or tumor sites, and viral load data should be interpreted with caution. Interestingly, in some cases, a transient rise in plasma EBV load occurred immediately after CTL infusions, a phenomenon recorded by others during treatment of PTLD with autologous CTLs and thought to indicate specific lysis of tumor cells.25
Heslop et al have previously shown that stem cell transplant donor-derived CTLs survive long term in recipients and can control reactivated persistent EBV infection up to 18 months after infusion.28 But considering the partial HLA matching and allogeneic nature of the CTLs used in this trial, we expected them to be short-lived in vivo since the mismatched HLA molecules would be targeted by the host immune system. However only one patient developed detectable antialloantibodies during the study, and this individual achieved a complete response. This finding can perhaps be explained by the immunosuppressive therapy that all patients were receiving inhibiting primary immune responses. Using clonotyping to monitor individual T-cell clones within infused CTLs, we demonstrated survival of these cells in peripheral blood for up to 7 days (Figure 5), and in one patient (patient 13) where tetramers were available to detect individual EBV peptide–specific clones, infused CTLs were detected at 194 days. In this case, the CTLs used contained a high level (34%) of CD4+ T cells, again suggesting that these cells may have prolonged in vivo survival (M.K.G. and D.H.C., data not shown).
Compared with our 52% response rate at 6 months, a recent phase 2 clinical trial using rituximab to treat PTLD reported a response rate of 44% at day 80. Rituximab is available for immediate use and is easy to administer. This study enrolled patients whose only previous treatment was reduction of immunosuppression, and CNS tumors were excluded, whereas, in our trial 50% of patients had received and failed on a variety of therapies in addition to reduction of immunosuppression (Tables 1, 2) and patients with CNS PTLD (n = 5) were included.12 Chemotherapy is commonly preferred for aggressive tumors and gives a comparable response rate to that reported here, however severe toxicity and infections are recurring problems.11,29 Thus there is an urgent need for large multicenter trials comparing and combining these treatment options in order to establish the best treatment practice for patients at all stages of the disease.
In summary, we have shown that partially HLA-matched allogeneic T-cell therapy is a safe and effective option for PTLD and that a CTL bank overcomes the restrictions implicit in autologous CTL therapy. During the trial, frozen CTLs were sent from Edinburgh to France, Sweden, and Australia where they were used to treat PTLD. Thus a single CTL bank could be a valuable international resource.
Contribution: D.H.C. was the principal investigator; D.H.C., T.H., M.T., P.L.A., and A.J.S. were grant holders; T.H. and D.H.C. designed the trial, supervised and trained the team members, liaised with clinicians, provided clinical advice, interpreted and analyzed data, and drafted the paper; G.M.W. was the trial coordinator, liaised with transplantation centers, and maintained databases; G.M.W., M.M.J., G.U., P.W., and D.B. established and maintained CTL bank, analyzed patients' samples, and performed quality control/sterility checks; M.M.J. also carried out EBV PCR; K.M. performed TCR spectratyping; C.D.H. performed statistical analyses; C.B. provided histologic diagnosis on tumor samples; M.T., P.L.A., and A.J.S. advised on trial design; M.T. coordinated the blood donors; P.L.A. provided clinical advice and phenotyping of cells; D.K., A.M., and M.K.G. enrolled 3 or more PTLD patients to the trial; all the authors read and commented on the final version of the paper.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Tanzina Haque, Centre for Virology, Royal Free Hospital and University College Medical School, Rowland Hill Street, London NW3 2PF; e-mail: t.haque{at}medsch.ucl.ac.uk.
The work was funded by The Cancer Research UK (grant nos. SP 2278/0202 and C307/A3869). The authors would like to thank the lead clinicians of the transplantation centers for referring patients to this trial: Dr Amrolia, Great Ormond Street Hospital, London; Dr Cavenagh, Barts and the London National Health Service Trust; Dr Culligan, Aberdeen Royal Infirmary; Dr Fitzsimons, Gartnavel General Hospital, Glasgow; Drs Gustafsson, Jernberg and Barkholt, Karolinska University Hospital, Stockholm, Sweden; Dr Hunter, Leicester Royal Infirmary; Dr Mackie, Western General Hospital, Edinburgh; Dr Marcus, Addenbrooke's Hospital, Cambridge; Dr Mead, Southampton General Hospital; Drs Minard and Mahlaoui at Hopital Necker Enfants-Malades, Paris, France; Prof Mufti and Dr Devereux, King's College Hospital, London; Dr O'Connor, The Royal Belfast Hospital For Sick Children; Dr Pettitt, Royal Liverpool University Hospital; Dr Picton, Manchester Royal Infirmary; Dr Poynton, University Hospital of Wales, Cardiff; and Drs Wright and Snowden, Royal Hallamshire Hospital, Sheffield. The authors also thank the coordinators and staff at all transplantation units for collecting and sending samples to Edinburgh. Hazel Gavin and Elaine Edgar provided secretarial help. Dr Jill Douglas provided technical help.
An Inside Blood analysis of this article appears in the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
- Submitted December 13, 2006.
- Accepted April 26, 2007.
- © 2007 by The American Society of Hematology


text:
She assaulted all of our senses; the deep rumblings not coming as a steady vibration that lulled you to sleep, but instead a shuddering of her soul. Emanating deep in the engine room and working its way up through the ship in every pipe, vent and valve until even the deck covers chattered. If she were human they were the DT tremors or the lungs of a pneumonia victim through stethoscope ears that identified death's rattle. Her shakes could be heard in every loose link of chain and felt in every door handle grasped.
The plastic pitcher of water in the galley erupted as if an invisible hail storm was contained in the clear cylinder. A glass half-full and abandoned, while the cook scurried to batten down everything in site, walked its way over to the edge of the table and toppled onto the linoleum covered deck. The spilled water could not decide if it was running north and south or east and west. Two metal canisters braced near each other tinkled in alarm as strong shakes climbed up the bolted counter's legs. My freighter was struggling and so was her crew.


text:
Canberra DJ Hire Call and Book Today 0418 71 55 61 ........... Your Local Mobile Dee Jay
Thursday, 8 March 2018
Enlighten: Family Sixties Fest at the Library
Over two fabulous Friday nights at Enlighten, bring the family and get your groove on at the National Library with a far-out 60s-themed kids disco, roving performers and art and craft activities, set against the backdrop of stunning architectural projections.
So there'll be plenty to twist and shout about at the disco in the Library foyer, where kids can test out their moves in a dance competition, while Canberra DJ Hire playing all the tunes.
Roving performers, including a wild and wacky hula hoop dancer and 'cirquaholic' glow circus performers from Fool Factory, will add a touch of whimsy.
The Library building will be open, so don't forget to step inside for snacks, drinks and free tours of our fabulous exhibition 1968: Changing Times.
Giants Vs Western Bulldogs
If you haven t got a ticket yet, don t worry because its FREE ENTRY for this one for tomorrow awesome clash up.
You can catch us Deejaying in the ''Fanzone'' too, with our DJ's playing a mix of all your favourite new and old party hits from 5:30pm until late
It's on people!Giants
Subscribe to: Posts (Atom)


text:
Diploma in Counselling
Level 5/6 accredited qualification
This diploma provides robust training developing students as ethical and professional therapists.
Exploring several therapeutic models, this diploma provides students with an integrative approach and can be tailored to those working with children and young people.
The diploma runs for two years, one half day per week (1pm-8:30pm) or two evenings per week (6-9:15pm) and the following criteria must be fulfilled for successful completion of the course:
- Certification as fit to practice-assessment & feedback workshops
- 100 practice hours gained in a voluntary settling
- Ongoing supervision with a BACP or UKCP registered supervisor (ratio of 1:8 for duration of clinical hours or a minimum of 1.5 hours per month)
- Completion of two reports from supervisor indicating staisfactory & ethical professional practice
- Successful completion of assignments and presentations
- Personal therapy hours certified by a BACP or UKCP registered therapist
- Attendance at a two day residential weekend
- Case study presentation and Q&A session
- Completion of training portfolio
- Attendance at two Professional Development workshops
- 90% attendance record required
The requirements for this course exceed others available however this course is taught at Level 6 and is designed to provide you with a high level of knowledge, clinical skills and a strong theoretical and ethical base to further develop as a competent practitioner. It is also designed to fulfil BACP's requirements for accredited courses.


text:
Once more, the 080 Barcelona Fashion will gather an exceptional casting to show the collections of the 31 designers and brands for next autumn-winter 2016-17 at Casa Llotja de Mar in Barcelona. New names along with familiar faces will take part in this 17th edition from February 1st to 5th in this privilege showcase of the best Catalan fashion.
Regarding women, one name stands out: Marina Pérez, the internationally-acclaimed Spanish model who has worked with the likes of Bulgari and Harper's Bazaar, will make a comeback and will walk the runway for many different designers: from Celia Vela to Manuel Bolaño, showing off her great versatility. Another model to highlight is Afrodita Dorado, who's on the rise nowadays and has worked with such avant-garde companies like Acne and Balenciaga. Mayka Merino is another name to point out because, despite being only 19 years old, she has already walked the runway for top fashion brands like Louis Vuitton and Prada. This will be her second 080 Barcelona Fashion where she will take part in nine shows, including CARLOTAOMS and Txell Miras. Like her, Steffy Argelich is another name in the emerging Spanish modelling sector that will be present at 080 Barcelona Fashion alongside popular names like Rocío Crusset, Alba Galocha, Dalianah Arekion, Marta Ortiz, Marta Aguilar, Mar González, Lucía Rivera, Joana Sanz, Amando Romero and Desirée Cordero –Miss España 2015-.
Moreover, the Brazilian Diane Contrerato leads the international group. Faithful to the Catalan runway, she's an internationally well-known model thanks to her jobs for Dior, Delpozo and W Magazine, among many others. With her, we'll also see other Brazilians like Carolina Thaler and Daniela Braga who, after walking as an angel for Victoria's Secret show, comes back to the 080 Barcelona Fashion. Along with them, we find other names, maybe less popular but promising like Kasia Jujeszca, Magdalena Jasek, Nastia Kusakina, Zhenya Katava and Magda Laguinge.
As for the male models the casting shows the same high level. There will be international famous names like Clément Chabernaud, a familiar face at the 080 Barcelona Fashion who has worked for top luxury and fashion brands like Gucci, Hermès and Michael Kors and is considered the best male model in the world; and Jon Kortajarena, another usual name who, throughout his career, has teamed up with companies like Tom Ford and Salvatore Ferragamo. But there will be also newcomers, of international influence, like Óskar Kindelan, Gerard Sabé and Jaime Ferrandis. Other models that stand out in this 17th edition are Juan Betancourt, Antonio Navas, Marçal Taberner, Sam Steele, Xavi Serrano, Piero Méndez, Baptiste Radufe and Rhys Pickering.


text:
There's this thing that happens all the time when you hear entertainers talking about other artists with whom they've collaborated.
They like to point out how generous the others are. Oh man, Bobby Deniro is such a generous actor... Wow, I mean working with Charlize was amazing. She is such a gift and so giving.
You get a lot of that in interviews.
Today's #thisiscrazylove2016 goes to an artist who is as generous as humanly possible. I've had many a chat with her online over the last few years and her encouragement has kept me going.
I've also noticed on the Facebook that she is the first to share and promote her friends videos online. She trumpets the success of others every chance she gets.
Her name is Dana Powell. We went to high school together. She was awesome then. And she's awesome now.
I've been thinking about sharing the crazy love with Dana for a few weeks but didn't know quite how to do it. Then tonight she did that thing she does often. She shared a video of one of her friends and it was hilarious.
So, in the spirit of that kind of sharing, please watch this one. This is Dana in her comedic element!
Click here and try not to laugh. I love this short film so much.
Just in case you missed the link: http://votd.tv/nominees/200/donation


text:
I'm a big fan of bees. I think we all should be. They pollinate so many of our fine foods; blueberries, onions, coconuts, cucumbers & cashews would not grace our tables if it weren't for these amazing little creatures.
And then of course there is honey. Sweet and silky, golden and rich. Before apiary, or beekeeping, came into existence honey was rare and prized, a luxury of the wealthy, a celebration food.
Honey production goes a little like this: bees feast on flowers and collect nectar in their mouths. The nectar mixes with enzymes in their saliva, and voila: honey. Well almost. The final magic touch happens back at the hive, when the bees flutter their wings over the nectar enzyme cocktail reducing the moisture content in the mixture. Who knew wings weren't just for flying?
I don't think anyone can argue with the notion that honey is holy; we have accounts of honey in nearly every religion. In Hinduism, honey or madhu, is known to be one the five elixirs of immortality. It is considered a sattvic food in Ayurveda and has a long history of being revered. During Rosh Hashanah, Jews dip apples in honey to mark the New Year, while John the Baptist is said to have lived in the wild for quite some time on the unique combination of locusts and honey. (Brooklyn dinner party anyone?)
But by far my favorite ritual that involves honey is the Buddhist festival of Madhu Purhima. During this festival monks are given honey to commemorate the story of Buddha's peace making retreat to the wilderness, where a monkey, kind soul that he was, brought the fasting Buddha, yes you guessed it, honey.
Now why might a monkey bring a fasting Buddha honey? Good question. I'll be so bold as to offer up a few ideas.
Perhaps monkeys were privy to the fact that raw honey is antibacterial, antiviral, antifungal and antioxidant, that it contains a large amount of friendly bacteria and is thus, a powerhouse for the immune system.
Perhaps knowing the mechanics of fasting the monkey wanted to help the Buddha with his blood sugar. Ancient Olympians were said to eat honey and figs to help with endurance. Recent research has shown that honey consumed during or before training can indeed help an athlete's performance by maintaining optimal blood sugar levels. The simple sugars in honey are released gradually into the bloodstream, which provides prolonged and sustained energy. Consumption of refined white sugar on the other hand (and it's even more evil twin high fructose corn syrup) gives a quick high followed by a quick crash that leaves you tired and craving more sugar.
And then there's always the chance the Buddha could've gotten a little rambunctious and busted his knee. Ok probably unlikely, but in the event he did honey could've come to his rescue. Honey possesses incredible wound and burn healing properties. Clinical observations have shown that honey rapidly clears infection, inflammation, swelling and pain.
Today honey quality is an issue, as is the health and longevity of our bees. Not all beekeeping practices are equal that's for sure and pollutants in the environment of the bees surely make their way into the honey the bees make. This can include things such as road tar and pesticides so choose your honey well. I also suggest buying your honey in glass. Besides being a more earth friendly container, I prefer glass because plastic bottles can leach harmful chemicals such as BPA's into your honey.
I also think it is important to remember that honey was once incredibly precious and that it is our modern technologies that have made it so plentiful. As with all sweets moderate consumption is best. It takes about 12 worker bees their entire life to make just one teaspoon of honey so I also suggest giving a little thanks with each spoonful you consume.
When selecting honey for its health benefits – be it for eating, drinking or by applying through the skin – it is raw honey that you are after. Raw honey is honey just as it exists in the beehive. When raw honey is extensively processed, heated, or cooked, the benefits of the phytonutrients are largely eliminated.
Go to your local greenmarket and meet your beekeeper! If you reside in NYC you can find a list of the greenmarkets in your area here: http://www.grownyc.org/ourmarkets
Visit The Honey Locator, provided by the National Honey Board, and search for local beekeepers by state: http://www.honeylocator.com/
* THE CURIOUS CAN SEE THE FULL LIST OF CROPS THAT BEES POLLINATE HERE: http://en.wikipedia.org/wiki/List_of_crop_plants_pollinated_by_bees
* FOR MORE ON WOUND HEALING & HONEY : http://bio.waikato.ac.nz/honey/evidence.shtml